Agenus (NASDAQ:AGEN) Releases Quarterly Earnings Results, Beats Expectations By $1.83 EPS

Agenus (NASDAQ:AGEN) announced its earnings results on Monday. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.83, Zacks reports. The firm had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million.

Agenus Price Performance

NASDAQ:AGEN opened at $3.29 on Tuesday. Agenus has a one year low of $1.38 and a one year high of $7.34. The company has a fifty day moving average price of $3.26 and a 200 day moving average price of $3.77. The stock has a market cap of $111.89 million, a P/E ratio of -1.54 and a beta of 1.57.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Arrowstreet Capital Limited Partnership acquired a new position in Agenus in the third quarter worth about $120,000. Virtu Financial LLC acquired a new stake in Agenus during the fourth quarter valued at approximately $108,000. Engineers Gate Manager LP bought a new stake in shares of Agenus in the 2nd quarter valued at approximately $108,000. Tower Research Capital LLC TRC grew its stake in shares of Agenus by 265.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 15,893 shares during the period. Finally, Invesco Ltd. acquired a new position in shares of Agenus in the 1st quarter worth approximately $88,000. 61.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.50.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.